United States Patent 12,576,089 (Momelotinib): Claim Scope, Likely Claim Construction, and US Patent Landscape for Baseline Platelet–Selected Post-JAK Therapy Myelofibrosis
US Patent 12,576,089 is a method-of-treatment claim set focused on momelotinib dosing and patient selection in myelofibrosis after prior JAK inhibitor exposure, with a specific baseline platelet-count window and additional washout language. The independent claim (claim 1) is anchored on four elements: (1) momelotinib (or a salt), (2) treating myelofibrosis, (3) prior JAK inhibitor treatment, and (4) a baseline platelet count between 100×10^9/L and <150×10^9/L. Dependent claims tighten the prior-treatment washout period, identify particular prior JAK inhibitors (ruxolitinib, fedratinib), specify adult populations with intolerance/inadequate response, and narrow disease subtype and physico-chemical form of momelotinib salts (including Form II).
What does claim 1 actually require?
Claim 1:
A method of treating myelofibrosis in a subject by administering a therapeutically effective amount of momelotinib (or salt) to a subject:
- (i) having myelofibrosis, and
- (ii) having baseline platelet count ≥100×10^9/L and <150×10^9/L, and
- who was previously treated with a JAK inhibitor.
Practical claim construction implications
- “Baseline platelet count” is outcome-determinative. The infringement analysis will turn on the platelet count measured for eligibility. The claim does not specify whether platelets must be measured at a particular timepoint, but dependent claim 2 supplies a timing framework (within one week prior to initiation).
- “Previously been treated with a JAK inhibitor” is broad on its face. It does not limit which JAK inhibitor, duration, dose, or reason for discontinuation, except that dependent claims 3-6 explicitly narrow to ruxolitinib and fedratinib and then add response/intolerance qualifiers.
- Disease scope is broad at the independent level. Dependent claims specify intermediate/high-risk, and primary vs post-PV/ET, but claim 1 reaches any “myelofibrosis” meeting the platelet and JAK-exposure requirements.
How dependent claims narrow the eligible population
? Baseline platelet timing and JAK washout
Claim 2: baseline platelet count determined within one week prior to initiation of momelotinib, and no prior JAK inhibitor therapy within at least 2 weeks before momelotinib initiation.
This is a key tightening lever. It converts the platelet selection from a generic threshold into a time-locked inclusion criterion. It also injects a discontinuation/washout condition that can be used to design around the claim if a competitor uses a different washout period, or if the eligibility platelet count is measured outside the one-week window.
? Prior JAK inhibitor identity
Claim 3: subject previously treated with ruxolitinib.
Claim 5: subject previously treated with fedratinib.
These are narrower subsets of claim 1. In enforcement terms, a plaintiff would typically prefer the most specific dependent claims that match real-world prescribing data.
? Response/intolerance qualifiers after the specific JAK inhibitors
Claim 4 (ruxolitinib subgroup): adult human with inadequate response or intolerance, or failed to respond or ceased to respond.
Claim 6 (fedratinib subgroup): adult human with inadequate response or intolerance, or failed to respond or ceased to respond.
These qualifiers matter because “previously treated” can be interpreted broadly, but “inadequate response/intolerant” constrains the clinical narrative needed to establish the eligibility predicate.
? Disease risk and subtype
Claim 7: myelofibrosis is intermediate or high-risk.
Claim 8: myelofibrosis is primary myelofibrosis (PMF).
Claim 9: myelofibrosis is post-polycythemia vera or post-essential thrombocythemia.
These depend on how the clinician codes the disease subtype and risk category. If risk is not assessed using the patent’s implied rubric, disputes may arise about whether the predicate is met. The claims, however, are binary category statements.
? Momelotinib chemical form
Claims 10-12: momelotinib salt selection chain:
- claim 10: momelotinib or pharmaceutically acceptable salt
- claim 11: momelotinib dihydrochloride monohydrate
- claim 12: momelotinib dihydrochloride monohydrate Form II
If a competitor uses a different salt form or polymorph, claims 10-12 may be avoidable while claim 1 (if read broadly to encompass any momelotinib) remains a risk. The most plausible design-around for salts is to use a different, non-covered form only if the independent claim is simultaneously avoided (which is usually harder because claim 1 already covers “momelotinib… or pharmaceutically acceptable salt”).
? Administration route and schedule
Claim 13: oral administration.
Claims 14-15: daily; once daily.
Schedule constraints are exploitable if a competitor uses intermittent dosing or different cadence. If momelotinib is administered differently, claim 13-15 can be targeted as non-infringed even if the patient-eligibility predicates are met.
? Dose ranges
Claims 16-17: therapeutically effective amount between 50 mg/day and 200 mg/day, and specifically 200, 150, or 100 mg/day.
These numeric constraints can be used to structure launch dosing, titration strategies, and label claims. If a competitor uses doses outside the claimed range or uses alternate dosing regimens not equal to 100/150/200 mg/day, it can potentially dodge those dependent claims.
Scope map: what is covered vs what is left open
Core protected concept (independent claim)
- Momelotinib + platelet window (100 to <150) + prior JAK inhibitor exposure + treating myelofibrosis.
Additional protected concepts (dependent claim layers)
- Eligibility mechanics: one-week platelet determination + at least 2-week JAK inhibitor washout.
- Prior JAK inhibitors: ruxolitinib and fedratinib.
- Clinical predicate: inadequate response/intolerance or cessation due to failure.
- Disease labeling: intermediate/high-risk; PMF; post-PV/ET.
- Pharmaceutical form: momelotinib dihydrochloride monohydrate; Form II.
- Dosing and administration: oral, daily, once daily; dose range and specific mg/day values.
What remains potentially broader
Because claim 1 does not specify:
- which JAK inhibitor,
- exact washout duration,
- platelet measurement timing,
- momelotinib salt form,
- dose beyond “therapeutically effective,”
the independent claim likely covers a wide band of real-world regimens that satisfy the platelet window and prior JAK exposure.
“How would a court likely read these words?” (enforcement-relevant issues)
Baseline platelet predicate
In practice, the key dispute is whether “baseline platelet count” is the first platelet measurement used for eligibility and whether it matches the time window in claim 2 when claim 2 is asserted. Claim 2 supplies the “within one week prior” requirement and thus can reduce ambiguity.
Prior JAK inhibitor exposure
The term “previously been treated” typically covers any prior course that ends before the momelotinib initiation. Claim 2 adds a washout floor for the dependent claim, which can become the key differentiator.
“Therapeutically effective amount”
This phrase can be interpreted with reference to clinical use and the specification’s exemplars. Dependent claim 16 narrows the dose range for those embodiments. Competitors staying within standard momelotinib practice and still using the platelet-selected, post-JAK population will remain exposed under claim 1.
Salt/form claims
Claims 10-12 reduce ambiguity for product form and polymorph. If enforcement focuses on those forms, proof will likely rely on product manufacturing records and analytical characterization.
Patent landscape: how this claim set typically sits in the broader momelotinib IP stack
A full US landscape requires the complete patent family, publication numbers, and prosecution history. None were provided beyond the claim text and the US patent number. Under strict operating constraints, a complete, citation-backed landscape cannot be produced from the information available.
What can be stated from the claim structure alone is the positioning of this patent in the IP stack: it is not an origin-of-molecule claim; it is a clinical-method selection patent that is designed to capture a specific post-JAK myelofibrosis subgroup with a platelet-defined starting threshold and a time-locked eligibility framework.
Likely adjacent claim themes in momelotinib families (inferred from claim style)
- Platelet-based dosing or eligibility criteria (hematologic selection).
- Post-JAK inhibitor treatment lines (ruxolitinib/fedratinib exposure).
- Salt/polymorph specific product coverage (dihydrochloride monohydrate Form II).
- Standardization of administration route and schedule (oral, once daily).
- Numeric dose ranges.
These are typical “next-layer” patent strategies after the core molecule is established: they create additional, narrower hooks that can persist even after earlier method patents narrow to specific patient subtypes or clinical use settings.
Business impact: where the claim set is likely to be strongest
- Clinically identifiable patient cohort. Baseline platelets 100 to <150×10^9/L and prior JAK exposure are measurable and common in real-world hematology workflows.
- Chain-of-dependent claims create multiple enforcement pathways. A plaintiff can choose claim 2 (timing and washout), claim 3-4 or 5-6 (specific prior JAK inhibitor), and claim 7-9 (disease subtype) based on documentation available in medical records and treatment histories.
- Dosing and schedule constraints support “claim chart” proof. Once-daily oral dosing and named dose levels (100/150/200 mg/day) are easier to match against prescribing and dispensing records.
- Salt/form claims strengthen product-specific enforcement. If a company controls supply chain and the claimed form is used, the product identification burden drops.
Key Takeaways
- Claim 1 is a platelet-window, post-JAK exposure treatment method: momelotinib (or salt) for myelofibrosis when baseline platelets are ≥100×10^9/L and <150×10^9/L, with prior JAK inhibitor treatment.
- Claim 2 adds enforceable eligibility mechanics: platelet count measured within one week prior to initiation and no JAK inhibitor therapy in the prior 2 weeks.
- Claims 3-6 and 7-9 multiply narrowing hooks by tying eligibility to ruxolitinib or fedratinib failure/intolerance and to intermediate/high-risk or PMF or post-PV/ET.
- Claims 10-12 narrow momelotinib to a specific salt form (dihydrochloride monohydrate, Form II), while claims 13-17 lock in oral, once-daily use and dose boundaries.
- Without full family data and prosecution documents, a complete, cited US patent landscape cannot be generated; however, this patent is clearly positioned as a patient-selection and method-layer in the momelotinib US IP perimeter.
FAQs
- Is the platelet count range the main differentiator? Yes. Claim 1 is specifically limited to baseline platelet count ≥100×10^9/L and <150×10^9/L.
- Does prior JAK inhibitor exposure need to be the same drug? No for claim 1, but yes for dependent claims: ruxolitinib (claims 3-4) or fedratinib (claims 5-6).
- Can a different timing of platelet measurement avoid infringement? It can avoid dependent claim 2 if platelet count is not determined within one week prior to initiation.
- Does changing momelotinib salt form help? It can avoid dependent claims 10-12 if a non-covered form is used, but claim 1 still covers momelotinib and “pharmaceutically acceptable salt” in general.
- Are dosing regimen changes a potential design-around? Yes for dependent claims 14-15 and 16-17 if administration is not once daily and dosing does not fall within 50-200 mg/day or the named 100/150/200 mg/day levels.
References
No sources were provided beyond the claim text and the patent number, so no APA citations can be supported under the constraints.
